Effects of Degludec/Liraglutide on Time in Range, Inflammation and Endothelial Function vs Insulin Basal Bolus in Diabetic Inpatients

NCT05360537 · Completed

Last updated 2026-05-28

This clinical trial is testing whether a combination of the medications degludec and liraglutide improves blood sugar control and blood vessel function in adults hospitalized with type 2 diabetes compared to standard insulin therapy.

Status Completed The study has finished.

Phase Phase 4 Monitors a drug already on the market.

Type Interventional (clinical trial)

Design Randomized, double-blind treatment study

Participants 100 people

Who can join Ages 18–90 · all sexes

Timeline Started 2021-04 · est. completion 2022-04

Where 1 site · Italy

What this study is testing ClinicalTrials.gov NCT05360537 ↗

Description as written by the study sponsor.

The study aims to evaluate the effects of Insulin Degludec/Liraglutide on glycemic variability assessed by continuous glycemic monitoring with the function time in range, serum markers of inflammation, markers of endothelial dysfunction and a possible correlation with intra and extra-hospital mortality rates in a group of hospitalized diabetic patients compared to a control group of in-patient diabetic in treatment on insulin Basal-bolus.

Treatments tested

Insulin Degludec / Liraglutide Injectable Product also known as Insulin Degludec/Liraglutide Drug

administration of Insulin Degludec/Liraglutide
Insulin Glargine also known as glargine Drug

Administration of glargine insulin

Main thing measured	Change of Time in Range % at 7 days, at 1 and 6 months
Sponsor	University of Palermo
Conditions studied	Diabetes Mellitus, Type 2
GLP-1 drugs	liraglutide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT05360537 ↗